Yarrow Bioscience grants CEO 465,857 stock options

The options vest on a schedule beginning July 28, 2027, with continued service required on each vesting date.

Available on EDGAR 10/30/2026 - 04:03 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Yarrow Bioscience, Inc. Chief Executive Officer Rebecca Frey received a direct grant of options covering 465,857 common shares on October 29, 2026, with an exercise price of $20.00 per share. One quarter vests on July 28, 2027, and the remaining three quarters vest in equal monthly installments over the following three years, subject to her continued service on each vesting date. The options expire October 29, 2036.

Insider Trade Summary

Grant/Award: 465,857 shares

Grant/Award 1 txn

Insider Frey Rebecca

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	465,857	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 465,857 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase 465,857 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Option grant: 465,857 options covering common shares Exercise price: $20.00 per share Initial vesting: One quarter +2 more

5 metrics

Option grant 465,857 options covering common shares Granted October 29, 2026

Exercise price $20.00 per share Options granted October 29, 2026

Initial vesting One quarter July 28, 2027, subject to continued service

Remaining vesting Three quarters in equal monthly installments over the following three years Subject to continued service on each vesting date

Option expiration October 29, 2036 Options granted October 29, 2026

Key Terms

Stock Option (Right to Buy), vest, continued service

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest financial

"one quarter of which will vest on July 28, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continued service financial

"subject to the Reporting Person's continued service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did YARW CEO Rebecca Frey receive?

Rebecca Frey received options covering 465,857 Yarrow Bioscience common shares on October 29, 2026. The options have a $20.00 per-share exercise price.

When do Rebecca Frey's YARW options vest?

One quarter vests on July 28, 2027, and the remaining three quarters vest in equal monthly installments over the following three years, subject to her continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frey Rebecca

(Last) (First) (Middle)

C/O YARROW BIOSCIENCE, INC.

470 JAMES STREET, SUITE 007

(Street)

NEW HAVEN CONNECTICUT 06513

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Yarrow Bioscience, Inc. [ YARW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	10/29/2026		A		465,857		(1)	10/29/2036	Common Stock	465,857	$0	465,857	D

Explanation of Responses:

1. This option represents a right to purchase 465,857 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Tyler Zeronda, as attorney-in-fact for Rebecca Frey	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)